Navigation Links
Isis Reports Financial Results and Highlights for First Quarter 2013
Date:5/7/2013

its partners in the first quarter.

Balance SheetAs of March 31, 2013, Isis had cash, cash equivalents and short-term investments of $371.9 million compared to $374.4 million at December 31, 2012 and had working capital of $361.5 million at March 31, 2013 compared to $349.1 million at December 31, 2012.  Isis maintained its cash position primarily due to the $32.5 million in milestone payments it received in the first quarter while continuing to invest in its pipeline. Isis' cash at March 31, 2013 does not include the $30 million upfront payment Isis received from Roche for Isis' HTT collaboration.  Isis' working capital increased in 2013 primarily due to an increase in current assets resulting from an increase in Isis' investment in Regulus. At March 31, 2013, the carrying value of Isis' investment in Regulus was $44.9 million compared to $33.6 million at December 31, 2012.

Business Highlights"We have had a number of important accomplishments already this year.  Together with Genzyme we brought KYNAMRO to the market in the United States for patients with HoFH.  We continued to mature and expand our severe and rare disease franchise, reporting early encouraging data on our first splicing drug, ISIS-SMNRx, in children with spinal muscular atrophy and initiating Phase 2/3 programs for ISIS-SMNRx with Biogen Idec and ISIS-TTRRx with GSK.  We plan to continue this momentum through the year.  Over the next couple of months we plan to report Phase 2 data on both ISIS-CRPRx and ISIS-APOCIIIRx," continued Ms. Parshall. 

"We continue to be successful in implementing our business strategy and establishing strategic partnerships that provide us with significant value.  The performance of our drugs in the clinic and the broad applicability of our antisense technology have generated significant interest in Isis.  One of our partnering goals is to selec
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Perrigo Reports Record Revenue and Adjusted Earnings
2. Discovery Labs Reports First Quarter 2013 Financial Results
3. Endo Reports First Quarter Financial Results
4. Landauer, Inc. Reports Fiscal 2013 Second Quarter Results
5. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
6. Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
7. IRIDEX Reports 2013 First Quarter Results
8. Masimo Reports First Quarter 2013 Financial Results
9. Neurocrine Biosciences Reports First Quarter 2013 Results
10. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
11. Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Simplified Genetics , the only provider ... and safety in the U.S., announced today the launch of ... improved overall health found within specific genes – all with ... The tests include Simply Fit and ... genetic analysis that maps four key genes to provide individuals ...
(Date:9/2/2015)... 2, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... and Chief Executive Officer, will present a corporate ... Conference, sponsored by H.C. Wainwright & ... 2015 at the St. Regis Hotel in New ...
(Date:9/2/2015)... SAINT PAUL, Minn. , Sept. 2, 2015 /PRNewswire/ ... company, today scheduled a conference call to discuss its ... ended July 31, 2015. The call will be at ... Company will report financial results for the third quarter ... September 10, 2015. Participants can dial ...
Breaking Medicine Technology:Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 2Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 3RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2
(Date:9/2/2015)... ... September 02, 2015 , ... A third party administrator (TPA) ... seeing a significant increase in unlawful tactics used by out-of-network (OON) ambulatory surgical ... of OON ASCs encouraging members to have elective procedures done at their facilities ...
(Date:9/2/2015)... ... 2015 , ... Amada Senior Care, premier provider of in-home care and assisted ... County location. Amada franchise partners Mike and Mell Fleming came to the senior ... over 20 years in medical device sales while Mell spent over 30 years as ...
(Date:9/2/2015)... ... September 02, 2015 , ... EDAC Systems, Inc., ... management solutions and services to both government and commercial clients, today announced the ... utility for IBM’s Datacap document capture platform. EDAC PurePAGE processes and enhances ...
(Date:9/2/2015)... ... 2015 , ... “ G-Hold ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... a tablet while reducing the likelihood of it dropping. , Tablets like the iPad ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Pentec Health, Inc., ... Inc. 5000 List for an impressive sixth consecutive year. Less than 5 % of ... twelve firms in the “health” sector. Pentec’s 3-year revenue growth rate of 65% ...
Breaking Medicine News(10 mins):Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... a Phase 1 clinical trial on a new experimental ... first new class of anti-TB drugs in the past ... and drug-resistant TB. The study is the first ... the National Institutes of Health through the Hinckley-based research ...
... protecting bikers, brains, may also be contributing to hearing ... find out why. The distinctive roar of a ... biggest source of noise for motorcyclists is actually generated ... legal speeds, the sound can exceed safe levels. Now, ...
... have received a major funding boost of 550,000 from ... into the pathological processes underpinning Alzheimer,s disease, the most ... the UK. The funding will be used to ... electrical signalling go wrong in the Alzheimer,s disease brain. ...
... (HealthDay News) -- Low blood pressure while undergoing dialysis ... blood vessels are connected to the dialysis machine, a ... a sudden drop in blood pressure during dialysis can ... and long-term problems such as stroke, seizure, heart damage ...
... research focusing on high-frequency oscillations, termed ripples and ... provide an important marker for the localization of ... to the study now available in Epilepsia ... Epilepsy (ILAE), the resection of brain regions containing ...
... Crawford, PhD, a clinical associate professor of psychiatry and ... at Boston University School of Medicine (BUSM), has been ... Excellence in Diversity Training by the Association of Psychology ... presented to Crawford during the American Psychological Association,s Convention ...
Cached Medicine News:Health News:Scientists receive funding boost to further research into disease mechanisms of Alzheimer’s 2Health News:Blood Pressure Drop During Dialysis May Raise Clot Risk 2Health News:Fast ripples confirmed to be valuable biomarker of area responsible for seizure activity in children 2
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: